Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARCT 
Arcturus Therapeutics Holdings Inc (ARCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ARCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $69.89
1 Year Target Price $69.89
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.35% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 469.77M USD | Price to earnings Ratio - | 1Y Target Price 69.89 |
Price to earnings Ratio - | 1Y Target Price 69.89 | ||
Volume (30-day avg) 11 | Beta 2.27 | 52 Weeks Range 8.04 - 25.88 | Updated Date 08/28/2025 |
52 Weeks Range 8.04 - 25.88 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When After Market | Estimate 3.21 | Actual -0.34 |
Profitability
Profit Margin -49.27% | Operating Margin (TTM) -41.04% |
Management Effectiveness
Return on Assets (TTM) -13% | Return on Equity (TTM) -24.58% |
Valuation
Trailing PE - | Forward PE 2.48 | Enterprise Value 299998806 | Price to Sales(TTM) 3.85 |
Enterprise Value 299998806 | Price to Sales(TTM) 3.85 | ||
Enterprise Value to Revenue 2.73 | Enterprise Value to EBITDA -25.67 | Shares Outstanding 27154500 | Shares Floating 25017468 |
Shares Outstanding 27154500 | Shares Floating 25017468 | ||
Percent Insiders 7.88 | Percent Institutions 89.25 |
Upturn AI SWOT
Arcturus Therapeutics Holdings Inc
Company Overview
History and Background
Arcturus Therapeutics Holdings Inc. was founded in 2013. It is a late-stage clinical mRNA medicines and vaccine company pursuing medicines for liver and respiratory diseases and vaccines.
Core Business Areas
- mRNA Medicines: Focuses on developing mRNA-based therapeutics for liver and respiratory diseases.
- Vaccines: Develops mRNA vaccines for infectious diseases.
- Therapeutic Discovery: Innovating in mRNA technology.
Leadership and Structure
Joseph E. Payne is the President & CEO. The company has a typical corporate structure with departments focused on research, development, clinical trials, and administration.
Top Products and Market Share
Key Offerings
- ARCT-154 (COVID-19 Vaccine): A second-generation mRNA COVID-19 vaccine candidate. Arcturus has partnered with several organizations globally. Competitors include Moderna (MRNA) and Pfizer (PFE).
- ARCT-810 (Ornithine Transcarbamylase (OTC) Deficiency): mRNA therapeutic in clinical development for OTC deficiency, a rare genetic liver disorder. Competitors include companies developing gene therapies for similar conditions.
Market Dynamics
Industry Overview
The mRNA therapeutics and vaccines market is rapidly growing, driven by the success of mRNA COVID-19 vaccines and increasing investment in the field. The growth is driven by advancements in mRNA technology and increased funding.
Positioning
Arcturus is a clinical-stage company with a differentiated mRNA delivery technology. It competes with larger pharmaceutical companies in both the therapeutics and vaccine space.
Total Addressable Market (TAM)
The overall mRNA therapeutics and vaccine market is estimated to be several tens of billions USD and growing fast. Arcturus is positioned to address specific segments within this large TAM by focusing on particular diseases and mRNA technologies.
Upturn SWOT Analysis
Strengths
- Proprietary mRNA delivery technology (LUNAR)
- Strong intellectual property portfolio
- Clinical-stage pipeline with multiple candidates
- Partnerships with established pharmaceutical companies
Weaknesses
- Reliance on partnerships for funding and commercialization
- Limited commercial infrastructure compared to larger competitors
- Dependence on successful clinical trial outcomes
- High R&D expenditure
Opportunities
- Expansion of pipeline into new therapeutic areas
- Further development of mRNA delivery technology
- Potential for regulatory approvals of lead candidates
- Strategic partnerships and collaborations
Threats
- Competition from larger pharmaceutical companies with more resources
- Clinical trial failures
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- LLY
- SNY
- AZN
Competitive Landscape
Arcturus is competing in a field dominated by much larger and more established pharmaceutical companies. Its advantages lie in its differentiated mRNA delivery technology and focused approach to specific therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Arcturus' growth has been driven by advancements in its mRNA technology and the progression of its clinical pipeline.
Future Projections: Future growth depends heavily on the success of its clinical trials and the ability to commercialize its products. Analyst estimates should be consulted for specific projections.
Recent Initiatives: Recent initiatives include advancing its COVID-19 vaccine program, expanding its pipeline of mRNA therapeutics, and strategic partnerships.
Summary
Arcturus Therapeutics is a clinical-stage company with a promising mRNA platform. Its strengths lie in its proprietary technology and early-stage pipeline, but it faces significant competition from larger players. Successful clinical trial outcomes are crucial for its future growth. The company must manage its cash burn and navigate regulatory hurdles carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arcturus Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcturus Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-04-16 | Founder, President, CEO & Director Mr. Joseph E. Payne M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 174 | Website https://arcturusrx.com |
Full time employees 174 | Website https://arcturusrx.com | ||
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.